Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: A pilot trial Journal Article
| Authors: | Schrag, D.; Weiser, M. R.; Goodman, K. A.; Gonen, M.; Hollywood, E.; Cercek, A.; Reidy-Lagunes, D. L.; Gollub, M. J.; Shia, J.; Guillem, J. G.; Temple, L. K.; Paty, P. B.; Saltz, L. B. |
| Article Title: | Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: A pilot trial |
| Abstract: | Although neoadjuvant chemoradiotherapy achieves low local recurrence rates in clinical stages II to III rectal cancer, it delays administration of optimal chemotherapy. We evaluated preoperative infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevacizumab with selective rather than consistent use of chemoradiotherapy. Thirty-two patients with clinical stages II to III rectal cancer participated in this single-center phase II trial. All were candidates for low anterior resection with total mesorectal excision (TME). Patients were to receive six cycles of FOLFOX, with bevacizumab included for cycles 1 to 4. Patients with stable/progressive disease were to have radiation before TME, whereas responders were to have immediate TME. Postoperative radiation was planned if R0 resection was not achieved. Postoperative FOLFOX × 6 was recommended, but adjuvant regimens were left to clinician discretion. The primary outcome was R0 resection rate. Between April 2007 and December 2008, 32 (100%) of 32 study participants had R0 resections. Two did not complete preoperative chemotherapy secondary to cardiovascular toxicity. Both had preoperative chemoradiotherapy and then R0 resections. Of 30 patients completing preoperative chemotherapy, all had tumor regression and TME without preoperative chemoradiotherapy. The pathologic complete response rate to chemotherapy alone was 8 of 32 (25%; 95% CI, 11% to 43%). The 4-year local recurrence rate was 0% (95% CI, 0% to 11%); the 4-year disease-free survival was 84% (95% CI, 67% to 94%). For selected patients with clinical stages II to III rectal cancer, neoadjuvant chemotherapy and selective radiation does not seem to compromise outcomes. Preoperative Radiation or Selective Preoperative Radiation and Evaluation Before Chemotherapy and TME (PROSPECT), a randomized phase III trial to validate this experience, is now open in the US cooperative group network. |
| Keywords: | adult; treatment outcome; aged; disease-free survival; middle aged; survival rate; bevacizumab; fluorouracil; adjuvant therapy; disease free survival; chemotherapy, adjuvant; neoadjuvant therapy; radiotherapy, adjuvant; cancer staging; antineoplastic agent; neoplasm staging; adenocarcinoma; phase 2 clinical trial; antineoplastic combined chemotherapy protocols; pathology; monoclonal antibody; pilot study; pilot projects; folinic acid; adjuvant chemotherapy; platinum complex; rectal neoplasms; rectum tumor; organoplatinum compounds; leucovorin; antibodies, monoclonal, humanized; adjuvant chemoradiotherapy; chemoradiotherapy, adjuvant; humans; human; male; female; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 6 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-02-20 |
| Start Page: | 513 |
| End Page: | 518 |
| Language: | English |
| DOI: | 10.1200/jco.2013.51.7904 |
| PUBMED: | 24419115 |
| PROVIDER: | scopus |
| PMCID: | PMC5795691 |
| DOI/URL: | |
| Notes: | Export Date: 1 May 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work